The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Highlights in NHL from ASCO: SHINE trial & racial disparities in CAR-T therapy access
Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, shares his highlights in non-Hodgkin lymphoma (NHL) from the ASCO 2022 meeting, discussing the results of the Phase III SHINE trial (NCT01776840) that showed a clear benefit in progression-free survival (PFS) for elderly patients with mantle cell lymphoma (MCL) treated with ibrutinib, bendamustine, and rituximab (BR) compared to patients treated with BR alone, and mentioning two abstracts highlighting racial disparities in access to CAR-T and standard therapies. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
